Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugssierra health and life Cimzia Coverage Update | Op…
    Ask Trek AI about this page
    Modifiedsierra health and lifePolicy 2026D0083L

    Cimzia (certolizumab pegol) coverage

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026D0083L alerts

    Get alerted when Policy 2026D0083L changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for Cimzia (certolizumab pegol) under the commercial medical benefit, listing indications, required trials/attestations, prescriber specialties, and authorization durations. Applies to members covered under the payer's UnitedHealthcare Commercial medical benefit rules.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    Payersierra health and life
    PolicyCimzia (certolizumab pegol) coverage
    Policy CodePolicy 2026D0083L
    Change TypeCoverage criteria revisedprescriber attestation addedexample agent lists updated
    Effective DateFeb 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation including prescriber attestation if patient or caregiver cannot self-administer and relevant prior therapy history.
    SourceLink
    POLICY UPDATE CHANGES

    Replaced references to 'targeted immunomodulator' with 'systemic targeted immunomodulator' in Coverage Rationale.

    Added prescriber attestation requirement that the patient or caregiver is not able or physically unable to self-administer Cimzia and that the prescriber must submit an explanation.

    Updated lists of systemic targeted immunomodulators that must not be used in combination with Cimzia for several indications (additions, removals, and replacements across indications).

    Removed CPT codes 96372 and 96401 from Applicable Codes.

    12 monthsauth duration
    Multipleindications covered
    Prohibitedcombination therapy
    J0717HCPCS
    02/01/2026policy effective

    Coverage Criteria by Indication

    Crohn's Disease (Initial and Continuation)

    Cimzia is proven and medically necessary for Crohn's disease when ALL of the following are met

    Initial therapy: Diagnosis of moderately to severely active Crohn's disease; and one of the following: history of inadequate response to conventional therapies (e.g., anti-inflammatory drugs, corticosteroids, or oral immunosuppressive agents) at maximally indicated doses unless contraindicated, OR prior treatment with an FDA‑approved systemic targeted immunomodulator for Crohn's disease (examples provided in policy), OR patient is currently on Cimzia; and Cimzia is initiated and titrated according to US FDA‑labeled dosing for Crohn's disease; and patient is not receiving Cimzia in combination with another systemic targeted immunomodulator for the same indication (examples listed in policy); and initial authorization will be issued for 12 months.

    Document prior therapy or prior targeted immunomodulator or current Cimzia use; prescriber attestation required when inability to self-administer is claimed.

    Attestation / specialist pathway (initial): When the prescriber attests that the patient or caregiver cannot be trained or are physically unable to self‑administer Cimzia, the prescriber must submit an explanation; Cimzia must be initiated and titrated per FDA dosing; patient must not be receiving Cimzia in combination with another systemic targeted immunomodulator for the same indication; prescribed by or in consultation with a gastroenterologist; initial authorization will be issued for 12 months.

    Prescriber attestation and gastroenterology involvement required for this pathway.

    Continuation therapy: Documentation of positive clinical response; Cimzia continued according to US FDA‑labeled dosing for Crohn's disease; patient is not receiving Cimzia in combination with another systemic targeted immunomodulator for the same indication (examples listed); authorization will be issued for 12 months.

    Continuation requires objective documentation of clinical benefit per policy.

    Rheumatoid Arthritis (Initial and Continuation)

    Cimzia is proven and medically necessary for rheumatoid arthritis when ALL of the following are met

    Initial therapy: Diagnosis of moderately to severely active rheumatoid arthritis; and one of the following: history of failure or intolerance to a 3‑month trial of one non‑biologic DMARD (e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine) at maximally indicated doses unless contraindicated, OR prior treatment with an FDA‑approved systemic targeted immunomodulator for rheumatoid arthritis, OR patient is currently on Cimzia; and Cimzia is initiated and titrated according to US FDA‑labeled dosing for RA; and patient is not receiving Cimzia in combination with another systemic targeted immunomodulator for the same indication (examples listed in policy); and initial authorization will be issued for 12 months.

    Requires documentation of prior DMARD trial or prior targeted therapy; prescriber attestation required if inability to self‑administer is claimed.

    Attestation / specialist pathway (initial): If prescriber attests patient or caregiver cannot be trained or are physically unable to self‑administer Cimzia, prescriber must submit explanation; Cimzia per FDA dosing; patient must not be receiving Cimzia with another systemic targeted immunomodulator for same indication; prescribed by or in consultation with a rheumatologist; initial authorization for 12 months.

    Rheumatology involvement required when attestation pathway used.

    Psoriatic Arthritis (Initial and Continuation)

    Cimzia is proven and medically necessary for psoriatic arthritis when ALL of the following are met

    Initial therapy: Diagnosis of active psoriatic arthritis; and one of the following: history of failure to a 3‑month trial of methotrexate at maximally indicated dose unless contraindicated, OR prior treatment with an FDA‑approved systemic targeted immunomodulator for PsA, OR patient is currently on Cimzia; and Cimzia is initiated and titrated according to US FDA‑labeled dosing for PsA; and patient is not receiving Cimzia in combination with another systemic targeted immunomodulator for the same indication (examples listed in policy); and initial authorization will be issued for 12 months.

    Specialist consult (rheumatology or dermatology) and prior methotrexate trial described for applicable pathways; prescriber attestation required if unable to self‑administer.

    Attestation / specialist pathway (initial): Prescriber attestation that the patient or caregiver cannot be trained or are physically unable to self‑administer Cimzia (explanation required); Cimzia per FDA dosing; patient not receiving Cimzia with another systemic targeted immunomodulator for same indication; prescribed by or in consultation with a rheumatologist or dermatologist; initial authorization 12 months.

    Attestation plus specialist involvement required for this pathway.

    Continuation therapy:

    Ankylosing Spondylitis / nr-axSpA (Initial and Continuation)

    Cimzia is proven and medically necessary for ankylosing spondylitis and non-radiographic axial spondyloarthritis when ALL of the following are met

    Initial therapy: Diagnosis of active ankylosing spondylitis or non‑radiographic axial spondyloarthritis; and one of the following: history of failure to two NSAIDs each used for at least 4 weeks at maximally indicated doses unless contraindicated, OR prior treatment with an FDA‑approved systemic targeted immunomodulator for AS/nr‑axSpA, OR patient is currently on Cimzia; and Cimzia is initiated and titrated according to US FDA‑labeled dosing for AS or nr‑axSpA; and patient is not receiving Cimzia in combination with another systemic targeted immunomodulator for the same indication (examples listed in policy); and initial authorization will be issued for 12 months.

    NSAID trial requirement applies to the standard initial pathway; prescriber attestation required when inability to self‑administer claimed.

    Attestation / specialist pathway (initial): Prescriber attestation that the patient or caregiver cannot be trained or are physically unable to self‑administer Cimzia (explanation required); Cimzia per FDA dosing; patient not receiving Cimzia in combination with another systemic targeted immunomodulator for same indication; prescribed by or in consultation with a rheumatologist; initial authorization 12 months.

    Rheumatology involvement required for this pathway.

    Plaque Psoriasis (Initial and Continuation)

    Cimzia is proven and medically necessary for plaque psoriasis when ALL of the following are met

    Initial therapy (standard): Diagnosis of moderate to severe plaque psoriasis; Cimzia initiated and titrated according to US FDA‑labeled dosing for PS; patient is not receiving Cimzia in combination with another systemic targeted immunomodulator for the same indication (examples listed in policy); and initial authorization will be issued for 12 months.

    This standard pathway applies when step therapy/prior systemic therapy criteria are not invoked.

    Initial therapy (step/alternatives): Either: (A) ≥3% body surface area involvement or palmoplantar, facial, genital, or severe scalp involvement AND history of failure to at least one topical therapy (examples listed) AND history of failure to a 3‑month trial of methotrexate at maximally indicated dose unless contraindicated; OR (B) prior treatment with an FDA‑approved systemic targeted immunomodulator for plaque psoriasis; OR (C) patient is currently on Cimzia.

    BSA and special site thresholds and topical/methotrexate trial requirements specified in policy.

    Attestation / specialist pathway (initial): When prescriber attests patient or caregiver cannot be trained or are physically unable to self‑administer Cimzia, prescriber must submit explanation; Cimzia per FDA dosing; patient not receiving Cimzia with another systemic targeted immunomodulator for same indication; prescribed by or in consultation with a dermatologist; initial authorization will be issued for 12 months.

    Plaque Psoriasis (Initial and Continuation Therapy)

    Cimzia is proven/medically necessary for plaque psoriasis when ALL of the following are met (initial and continuation branches are specified):

    Initial therapy — basic requirements: Diagnosis of moderate to severe plaque psoriasis; Cimzia initiated and titrated per US FDA‑labeled dosing for PS; patient is not receiving Cimzia in combination with a systemic targeted immunomodulator for the same indication (examples listed in policy); initial authorization for 12 months.

    Basic initial pathway.

    Initial therapy — step therapy options: Either (1) ≥3% BSA involvement or palmoplantar/facial/genital/severe scalp involvement AND history of failure to at least one topical therapy (specified list) AND history of failure to a 3‑month trial of methotrexate at maximally indicated dose unless contraindicated; OR (2) prior treatment with an FDA‑approved systemic targeted immunomodulator for plaque psoriasis (examples listed); OR (3) patient is currently on Cimzia.>= 3% BSA

    Encodes the nested AND/OR logic for PS initial pathways as specified in policy.

    Administration/attestation pathway:

    Polyarticular Juvenile Idiopathic Arthritis (Initial and Continuation Therapy)

    Cimzia is proven and medically necessary for active PJIA when ALL of the following are met (initial and continuation branches):

    Initial therapy: Diagnosis of active polyarticular juvenile idiopathic arthritis (PJIA); Cimzia initiated and titrated according to US FDA‑labeled dosing for PJIA; patient is not receiving Cimzia in combination with another systemic targeted immunomodulator for the same indication (examples listed in policy); initial authorization is for no more than 12 months.

    Standard initial pathway for PJIA.

    Attestation / specialist pathway (initial): When prescriber attests patient or caregiver cannot be trained or are physically unable to self‑administer Cimzia (explanation required), Cimzia must be initiated and titrated per FDA dosing; patient not receiving Cimzia with another systemic targeted immunomodulator for same indication; prescribed by or in consultation with a rheumatologist; initial authorization for no more than 12 months.

    Prescriber attestation plus rheumatology involvement required for this pathway.

    Continuation therapy: Patient has previously received Cimzia injection for intravenous infusion (documented), and documentation of positive clinical response; Cimzia dosed according to FDA‑labeled dosing for PJIA; patient not receiving Cimzia in combination with another systemic targeted immunomodulator for same indication; authorization for no more than 12 months.

    General Coverage Requirements (excerpt)

    Policy updated to require prescriber attestation and to revise example lists of systemic targeted immunomodulators for multiple indications.

    General requirements (excerpt): Prescriber attestation that the patient or caregiver cannot be trained or are physically unable to self‑administer Cimzia must be provided when required; documentation of prior therapies or prior targeted immunomodulator exposure and absence of prohibited concomitant systemic targeted immunomodulators is required per indication (updated example agent lists are included in the policy).

    Operational changes include replacing 'targeted immunomodulator' with 'systemic targeted immunomodulator' and adding a prescriber attestation requirement; see policy summary of changes for agents added/removed.

    Requests for Cimzia (certolizumab pegol) will not meet coverage criteria when the drug is prescribed in combination with another systemic targeted immunomodulator for treatment of the same indication. The policy explicitly lists example systemic targeted immunomodulators that are not permitted to be used concomitantly with Cimzia for each indication and states that such combination use risks denial of the request.

    Providers should confirm that the patient is not receiving any of the named systemic targeted immunomodulators (examples vary by indication) before submitting a prior authorization request; combination therapy exclusions apply to both initial and continuation authorizations and authorizations are typically issued for 12 months when criteria are met.

    For plaque psoriasis, polyarticular juvenile idiopathic arthritis, and other covered indications, the policy reiterates that Cimzia must not be used together with another systemic targeted immunomodulator for the same indication. Requests where the member is receiving combination targeted therapy are subject to review and may be denied as not meeting the coverage criteria.

    When preparing an authorization request, ensure documentation demonstrates the patient is not concurrently treated with listed systemic targeted immunomodulators for that specific indication and include clinical rationale supporting monotherapy with Cimzia when applicable.

    The policy provides updated example lists of systemic targeted immunomodulators that must not be used in combination with Cimzia for the same indication. Examples added across indications include agents such as Entyvio (vedolizumab), Omvoh (mirikizumab-mrkz), Tremfya (guselkumab), Bimzelx (bimekizumab-bkzx), Cosentyx (secukinumab), Taltz (ixekizumab), Sotyktu (deucravacitinib), and others; certain agents were removed or renamed in the lists per the revision notes.

    These example lists are indication-specific (Crohn's disease, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis/nr-axSpA, plaque psoriasis, PJIA) and are intended to guide prior authorization review — the presence of a listed agent being used concurrently with Cimzia for the same indication is a basis for non-coverage under this policy.

    If a request is submitted for plaque psoriasis (PS) or polyarticular juvenile idiopathic arthritis (PJIA) while the patient is receiving Cimzia in combination with a listed systemic targeted immunomodulator for the same indication, the request does not meet the policy criteria and may be considered not medically necessary.

    The policy requires reviewers to confirm concurrent medication lists; for situations where the patient is on combination therapy, the provider should document clinical justification and, where possible, transition plans — absent such documentation, prior authorization may be denied.

    This Medical Benefit Drug Policy is informational and must be used together with the member-specific benefit plan. In the event of a conflict between this policy and the member-specific benefit plan document, the member-specific plan governs and its terms determine coverage.

    Additionally, the policy revision adds an operational requirement for prescriber attestation regarding inability to self-administer Cimzia and clarifies that documentation and any requested explanations must be submitted with the authorization; failure to provide required attestation or plan-specific documentation may affect coverage decisions.

    Applicable Codes and Diagnostic Criteria

    Applicable ICD-10 CodesICD-10
    M06.049Rheumatoid arthritis without rheumatoid factor, unspecified hand
    M06.051Rheumatoid arthritis without rheumatoid factor, right hip
    M06.052Rheumatoid arthritis without rheumatoid factor, left hip
    M06.059Rheumatoid arthritis without rheumatoid factor, unspecified hip
    M06.061Rheumatoid arthritis without rheumatoid factor, right knee
    M06.062Rheumatoid arthritis without rheumatoid factor, left knee
    M06.069Rheumatoid arthritis without rheumatoid factor, unspecified knee
    M06.071Rheumatoid arthritis without rheumatoid factor, right ankle and foot
    M06.072Rheumatoid arthritis without rheumatoid factor, left ankle and foot
    M06.079Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot
    1–10 of 20
    1/2
    Applicable ICD-10 CodesICD-10
    M08.0AUnspecified juvenile rheumatoid arthritis, other specified site
    M08.012Unspecified juvenile rheumatoid arthritis, left shoulder
    M08.019Unspecified juvenile rheumatoid arthritis, unspecified shoulder
    M08.022Unspecified juvenile rheumatoid arthritis, left elbow
    M08.029Unspecified juvenile rheumatoid arthritis, unspecified elbow
    M08.031Unspecified juvenile rheumatoid arthritis, right wrist
    M08.032Unspecified juvenile rheumatoid arthritis, left wrist
    M08.039Unspecified juvenile rheumatoid arthritis, unspecified wrist
    M08.041Unspecified juvenile rheumatoid arthritis, right hand
    M08.042Unspecified juvenile rheumatoid arthritis, left hand
    1–10 of 11
    1/2
    Applicable ICD-10 CodesICD-10
    M08.051Unspecified juvenile rheumatoid arthritis, right hip
    M08.052Unspecified juvenile rheumatoid arthritis, left hip
    M08.059Unspecified juvenile rheumatoid arthritis, unspecified hip
    M08.061Unspecified juvenile rheumatoid arthritis, right knee
    M08.062Unspecified juvenile rheumatoid arthritis, left knee
    M08.069Unspecified juvenile rheumatoid arthritis, unspecified knee
    M08.071Unspecified juvenile rheumatoid arthritis, right ankle and foot
    M08.072Unspecified juvenile rheumatoid arthritis, left ankle and foot
    M08.079Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot
    Applicable ICD-10 CodesICD-10
    M08.08Unspecified juvenile rheumatoid arthritis, vertebrae
    M08.09Unspecified juvenile rheumatoid arthritis, multiple sites
    M08.1Juvenile ankylosing spondylitis
    M08.20Juvenile rheumatoid arthritis with systemic onset, unspecified site
    M08.211Juvenile rheumatoid arthritis with systemic onset, right shoulder
    M08.212Juvenile rheumatoid arthritis with systemic onset, left shoulder
    M08.219Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder
    Applicable ICD-10 CodesICD-10
    M08.221Juvenile rheumatoid arthritis with systemic onset, right elbow
    M08.222Juvenile rheumatoid arthritis with systemic onset, left elbow
    M08.229Juvenile rheumatoid arthritis with systemic onset, unspecified elbow
    M08.231Juvenile rheumatoid arthritis with systemic onset, right wrist
    M08.232Juvenile rheumatoid arthritis with systemic onset, left wrist
    M08.239Juvenile rheumatoid arthritis with systemic onset, unspecified wrist
    M08.241Juvenile rheumatoid arthritis with systemic onset, right hand
    M08.242Juvenile rheumatoid arthritis with systemic onset, left hand
    M08.249Juvenile rheumatoid arthritis with systemic onset, unspecified hand
    Applicable ICD-10 CodesICD-10
    M08.251Juvenile rheumatoid arthritis with systemic onset, right hip
    M08.252Juvenile rheumatoid arthritis with systemic onset, left hip
    M08.259Juvenile rheumatoid arthritis with systemic onset, unspecified hip
    M08.261Juvenile rheumatoid arthritis with systemic onset, right knee
    M08.262Juvenile rheumatoid arthritis with systemic onset, left knee
    M08.269Juvenile rheumatoid arthritis with systemic onset, unspecified knee
    M08.271Juvenile rheumatoid arthritis with systemic onset, right ankle and foot
    M08.272Juvenile rheumatoid arthritis with systemic onset, left ankle and foot
    M08.279Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot
    Applicable ICD-10 CodesICD-10
    M08.28Juvenile rheumatoid arthritis with systemic onset, vertebrae
    M08.29Juvenile rheumatoid arthritis with systemic onset, multiple sites
    M08.2AJuvenile rheumatoid arthritis with systemic onset, other specified site
    M08.3Juvenile rheumatoid polyarthritis (seronegative)
    M08.80Other juvenile arthritis, unspecified site
    M08.811Other juvenile arthritis, right shoulder
    M08.812Other juvenile arthritis, left shoulder
    M08.819Other juvenile arthritis, unspecified shoulder
    Applicable ICD-10 CodesICD-10
    M08.821Other juvenile arthritis, right elbow
    M08.822Other juvenile arthritis, left elbow
    M08.829Other juvenile arthritis, unspecified elbow
    M08.831Other juvenile arthritis, right wrist
    M08.832Other juvenile arthritis, left wrist
    M08.839Other juvenile arthritis, unspecified wrist
    M08.841Other juvenile arthritis, right hand
    M08.842Other juvenile arthritis, left hand
    M08.849Other juvenile arthritis, unspecified hand
    Applicable ICD-10 CodesICD-10
    M08.851Other juvenile arthritis, right hip
    M08.852Other juvenile arthritis, left hip
    M08.859Other juvenile arthritis, unspecified hip
    M08.861Other juvenile arthritis, right knee
    M08.862Other juvenile arthritis, left knee
    M08.869Other juvenile arthritis, unspecified knee
    M08.871Other juvenile arthritis, right ankle and foot
    M08.872Other juvenile arthritis, left ankle and foot
    M08.879Other juvenile arthritis, unspecified ankle and foot
    M08.88Other juvenile arthritis, vertebrae
    1–10 of 11
    1/2
    Applicable ICD-10 CodesICD-10
    M08.90Juvenile arthritis, unspecified, unspecified site
    M08.9AJuvenile arthritis, unspecified, other specified site
    M08.911Juvenile arthritis, unspecified, right shoulder
    M08.912Juvenile arthritis, unspecified, left shoulder
    M08.919Juvenile arthritis, unspecified, unspecified shoulder
    M08.921Juvenile arthritis, unspecified, right elbow
    M08.922Juvenile arthritis, unspecified, left elbow
    M08.929Juvenile arthritis, unspecified, unspecified elbow
    M08.931Juvenile arthritis, unspecified, right wrist
    M08.932Juvenile arthritis, unspecified, left wrist
    Applicable ICD-10 CodesICD-10
    M08.939Juvenile arthritis, unspecified, unspecified wrist
    M08.941Juvenile arthritis, unspecified, right hand
    M08.942Juvenile arthritis, unspecified, left hand
    M08.949Juvenile arthritis, unspecified, unspecified hand
    M08.951Juvenile arthritis, unspecified, right hip
    M08.952Juvenile arthritis, unspecified, left hip
    M08.959Juvenile arthritis, unspecified, unspecified hip
    M08.961Juvenile arthritis, unspecified, right knee
    M08.962Juvenile arthritis, unspecified, left knee
    M08.969Juvenile arthritis, unspecified, unspecified knee
    Applicable ICD-10 CodesICD-10
    M08.971Juvenile arthritis, unspecified, right ankle and foot
    M08.972Juvenile arthritis, unspecified, left ankle and foot
    M08.979Juvenile arthritis, unspecified, unspecified ankle and foot
    M08.98Juvenile arthritis, unspecified, vertebrae
    M08.99Juvenile arthritis, unspecified, multiple sites
    M45.0Ankylosing spondylitis of multiple sites in spine
    M45.1Ankylosing spondylitis of occipito-atlanto-axial region
    M45.2Ankylosing spondylitis of cervical region
    M45.3Ankylosing spondylitis of cervicothoracic region
    Applicable ICD-10 CodesICD-10
    M45.4Ankylosing spondylitis of thoracic region
    M45.5Ankylosing spondylitis of thoracolumbar region
    M45.6Ankylosing spondylitis lumbar region
    M45.7Ankylosing spondylitis of lumbosacral region
    M45.8Ankylosing spondylitis sacral and sacrococcygeal region
    M45.9Ankylosing spondylitis of unspecified sites in spine
    M45.A0Non-radiographic axial spondyloarthritis of unspecified sites in spine
    M45.A1Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region
    M45.A2Non-radiographic axial spondyloarthritis of cervical region
    Applicable ICD-10 CodesICD-10
    M45.A3Non-radiographic axial spondyloarthritis of cervicothoracic region
    M45.A4Non-radiographic axial spondyloarthritis of thoracic region
    M45.A5Non-radiographic axial spondyloarthritis of thoracolumbar region
    M45.A6Non-radiographic axial spondyloarthritis of lumbar region
    M45.A7Non-radiographic axial spondyloarthritis of lumbosacral region
    M45.A8Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region
    M45.ABNon-radiographic axial spondyloarthritis of multiple sites in spine
    M46.80Other specified inflammatory spondylopathies, site unspecified
    M46.81Other specified inflammatory spondylopathies, occipito-atlanto-axial region
    Applicable ICD-10 CodesICD-10
    M46.82Other specified inflammatory spondylopathies, cervical region
    M46.83Other specified inflammatory spondylopathies, cervicothoracic region
    M46.84Other specified inflammatory spondylopathies, thoracic region
    M46.85Other specified inflammatory spondylopathies, thoracolumbar region
    M46.86Other specified inflammatory spondylopathies, lumbar region
    M46.87Other specified inflammatory spondylopathies, lumbosacral region
    M46.88Other specified inflammatory spondylopathies, sacral and sacrococcygeal region
    M46.89Other specified inflammatory spondylopathies, multiple sites in spine
    M48.8X1Other specified spondylopathies, occipito-atlanto-axial region
    Applicable ICD-10 CodesICD-10
    M48.8X2Other specified spondylopathies, cervical region
    M48.8X3Other specified spondylopathies, cervicothoracic region
    M48.8X4Other specified spondylopathies, thoracic region
    M48.8X5Other specified spondylopathies, thoracolumbar region
    M48.8X6Other specified spondylopathies, lumbar region
    M48.8X7Other specified spondylopathies, lumbosacral region
    M48.8X8Other specified spondylopathies, sacral and sacrococcygeal region
    M48.8X9Other specified spondylopathies, site unspecified
    N82.2Fistula of vagina to small intestine
    Applicable ICD-10 CodesICD-10
    N82.3Fistula of vagina to large intestine
    N82.4Other female intestinal-genital tract fistulae

    Prior Authorization, Documentation, and Prescriber Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Cimzia. Initial authorizations are typically issued for 12 months. Requests for continuation/renewal also require prior authorization and, when approved, authorizations are generally issued for 12 months.

    • Initial authorization duration: 12 months (unless otherwise specified).
    • Continuation/renewal authorization duration: 12 months (documentation of ongoing response required).
    Documentation Required

    Authorization Duration and Renewal Requirements

    Authorization renewal requires documentation of a positive clinical response to Cimzia. Renewal requests must include clinical notes or other objective information demonstrating treatment benefit since the prior authorization period.

    • Include objective evidence of improvement (e.g., disease activity scores, clinician assessment, decrease in steroid use, improved signs/symptoms).

    Initial Therapy Requirements

    Initial Therapy — per-indication initial therapy rules

    Initial therapy rules vary by indication but generally require diagnosis, prior therapy failure or prior targeted therapy, adherence to FDA dosing, absence of combination targeted therapy for same indication, and prescriber specialty or attestation when specified.

    Initial Therapy — general: Diagnosis consistent with the FDA‑approved indication for the requested condition; required prior trials or prior systemic targeted immunomodulator exposure as specified per indication (examples provided in policy); Cimzia initiated and titrated according to US FDA‑labeled dosing for the indication; patient must not be receiving Cimzia in combination with another systemic targeted immunomodulator for the same indication; prescriber attestation and specialist involvement as required by indication; initial authorization typically issued for 12 months.

    See indication‑specific criteria for detailed prior trial requirements (e.g., DMARDs, NSAIDs, topical therapies, methotrexate).

    Indication‑specific prior therapy examples: Per indication, initial therapy pathways may be met by: failure of conventional therapies (e.g., corticosteroids, non‑biologic DMARDs, NSAIDs), OR prior treatment with an FDA‑approved systemic targeted immunomodulator for that indication, OR current use of Cimzia. Updated example lists of systemic targeted immunomodulators are provided in the policy summary of changes.

    Exact sequencing and agent lists are in the detailed indication sections of the policy.

    Continuation / Renewal Requirements

    Continuation Therapy — documentation of positive clinical response and adherence to dosing; typical 12-month approvals

    Continuation criteria generally require documentation of positive clinical response and adherence to FDA dosing; authorizations are typically issued for 12 months.

    Continuation — general: Documentation of positive clinical response to Cimzia; continued dosing consistent with US FDA‑labeled regimen for the treated indication; prescriber attestation when inability to self‑administer is claimed (explanation required); patient must not be receiving Cimzia in combination with another systemic targeted immunomodulator for the same indication; authorization typically issued for 12 months.

    Applies across covered indications for continuation.

    Continuation Therapy — continuation requires documentation of positive clinical response and adherence to FDA dosing

    Continuation requires documentation of positive clinical response and adherence to FDA dosing; authorizations issued for up to 12 months.

    Continuation — per‑indication specifics: For continuation, documentation of positive clinical response is required; Cimzia must be continued according to FDA‑labeled dosing for the specific indication; patient must not be receiving Cimzia in combination with another systemic targeted immunomodulator for the same indication; authorization will be issued for 12 months (or no more than 12 months for PJIA).

    Step Therapy and Prior Treatment Requirements

    Indication (per‑indication)Prior trial or treatment requirement (per policy text)
    Crohn's disease (CD)Diagnosis of moderately to severely active CD AND history of failure to one conventional therapy (e.g., corticosteroids) at up to maximally indicated doses unless contraindicated; OR prior treatment with an FDA‑approved systemic targeted immunomodulator for CD; OR currently on Cimzia.
    Rheumatoid arthritis (RA)Diagnosis of moderately to severely active RA AND history of failure/intolerance to a 3‑month trial of one non‑biologic DMARD at maximally indicated doses unless contraindicated; OR prior treatment with an FDA‑approved systemic targeted immunomodulator for RA; OR currently on Cimzia.
    Psoriatic arthritis (PsA)Diagnosis of active PsA AND history of failure to a 3‑month trial of methotrexate at maximally indicated dose unless contraindicated; OR prior treatment with an FDA‑approved systemic targeted immunomodulator for PsA; OR currently on Cimzia.
    Ankylosing spondylitis / nr‑axSpADiagnosis of active AS or nr‑axSpA AND history of failure to two NSAIDs (each used ≥4 weeks at maximally indicated doses) unless contraindicated; OR prior treatment with an FDA‑approved systemic targeted immunomodulator for AS/nr‑axSpA; OR currently on Cimzia.
    Plaque psoriasis (PS)Diagnosis of moderate to severe PS AND either (A) ≥3% BSA or special‑site involvement AND failure to ≥1 topical therapy AND failure to a 3‑month methotrexate trial at maximally indicated dose unless contraindicated; OR (B) prior treatment with an FDA‑approved systemic targeted immunomodulator for PS; OR (C) currently on Cimzia.
    Polyarticular juvenile idiopathic arthritis (PJIA)Diagnosis of active PJIA AND Cimzia initiated per FDA dosing; not used in combination with another systemic targeted immunomodulator for same indication; prescriber attestation and rheumatology involvement required for certain pathways; initial authorization up to 12 months.
    Plaque psoriasis step requirementPolicy detail / alternate pathways
    Topical therapy requirementHistory of failure to one topical therapy unless contraindicated; topical agents listed include corticosteroids, vitamin D analogs, tazarotene, calcineurin inhibitors, anthralin, coal tar (policy lists these by example).
    Methotrexate requirementHistory of failure to a 3‑month trial of methotrexate at the maximally indicated dose unless contraindicated or clinically significant adverse effects are experienced.
    Alternate pathways meeting step therapyAlternative initial pathways include prior treatment with an FDA‑approved systemic targeted immunomodulator for plaque psoriasis, or current use of Cimzia; prescriber attestation pathway (inability to self‑administer) with dermatologist involvement is also described in the policy.
    IndicationUpdated systemic targeted immunomodulators — examples for prior treatment or prohibited combination
    Crohn's diseaseExamples updated — added: vedolizumab (Entyvio), mirikizumab (Omvoh), guselkumab (Tremfya); removed: etanercept (Enbrel), baricitinib (Olumiant), abatacept (Orencia), golimumab (Simponi), tofacitinib (Xeljanz); naming standardized for ustekinumab.
    Psoriatic arthritisExamples updated — added: bimekizumab (Bimzelx); removed: baricitinib (Olumiant); standardized ustekinumab; Xeljanz replaced with Xeljanz/Xeljanz XR where indicated.
    Ankylosing spondylitis / nr‑axSpAExamples updated — added: bimekizumab (Bimzelx), secukinumab (Cosentyx), ixekizumab (Taltz); prior‑treatment examples expanded to include enbrel (etanercept), baricitinib (Olumiant), abatacept (Orencia), ixekizumab (Taltz); Xeljanz replaced with Xeljanz/Xeljanz XR.
    Plaque psoriasisExamples updated — added: bimekizumab (Bimzelx), deucravacitinib (Sotyktu); removed: baricitinib (Olumiant), abatacept (Orencia), upadacitinib (Rinvoq), golimumab (Simponi), tofacitinib (Xeljanz); prior‑treatment examples added bimekizumab, secukinumab (Cosentyx), etanercept (Enbrel), tildrakizumab (Ilumya), brodalumab (Siliq), deucravacitinib (Sotyktu), ixekizumab (Taltz); naming standardized for ustekinumab.
    Polyarticular juvenile idiopathic arthritisExamples updated to reflect replacement of Xeljanz with Xeljanz/Xeljanz XR naming and other adjustments to example lists for prohibited combinations.

    Background and Drug Information

    Cimzia (certolizumab pegol) is a recombinant humanized antibody Fab' fragment that binds tumor necrosis factor alpha (TNF‑α). The molecule is PEGylated to extend half‑life and, as a Fab' fragment, it lacks an Fc region and does not fix complement or cause antibody‑dependent cytotoxicity.

    Cimzia is an anti‑TNF agent indicated for multiple inflammatory conditions addressed in this policy, including Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis/non‑radiographic axial spondyloarthritis, moderate‑to‑severe plaque psoriasis, and polyarticular juvenile idiopathic arthritis (age ≥2).

    Crohn's disease (moderately to severely active)
    DefinitionModerately to severely active Crohn's disease
    Initial therapy conditionsDiagnosis of moderately to severely active Crohn's disease plus inadequate response to conventional therapies (examples: anti‑inflammatory drugs, corticosteroids, oral immunosuppressive agents)
    Continuation requirementDocumentation of positive clinical response and adherence to FDA dosing for Crohn's disease

    Policy Revision Notes

    2026-02-01policy_revisionLatest

    Policy revised to (1) require prescriber attestation that the patient or caregiver cannot be trained or are physically unable to self-administer Cimzia, and (2) replace generic 'targeted immunomodulator' language with 'systemic targeted immunomodulator' in coverage rationale and combination-therapy exclusions; example lists of systemic targeted immunomodulators were added/updated across multiple indications.

    2026-02-01operational_update

    Updated example lists of systemic targeted immunomodulators for multiple indications (additions, removals, and replacements across Crohn's disease, RA, PsA, AS/nr-axSpA, plaque psoriasis, and pJIA).

    Material operational changes in the 02/01/2026 revision include a requirement for a prescriber attestation when the patient or caregiver cannot be trained or are physically unable to self‑administer Cimzia; the prescriber must submit an explanation with the authorization request.

    Policy Summary
    Payersierra health and life
    PolicyCimzia (certolizumab pegol) coverage
    Policy CodePolicy 2026D0083L
    Change TypeCoverage criteria revisedprescriber attestation addedexample agent lists updated
    Effective DateFeb 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation including prescriber attestation if patient or caregiver cannot self-administer and relevant prior therapy history.
    SourceLink
    On This Page
    Coverage Criteria by IndicationApplicable Codes and Diagnostic CriteriaPrior Authorization, Documentation, and Prescriber RequirementsInitial Therapy RequirementsContinuation / Renewal RequirementsStep Therapy and Prior Treatment RequirementsBackground and Drug InformationPolicy Revision Notes
    Continuation therapy: Documentation of positive clinical response; Cimzia initiated and titrated per US FDA dosing for RA; prescriber attestation if inability to self‑administer is claimed (explanation required); patient not receiving Cimzia in combination with another systemic targeted immunomodulator for same indication; authorization will be issued for 12 months.

    Continuation requires documentation of clinical benefit and adherence to FDA dosing.

    Documentation of positive clinical response; Cimzia initiated and titrated per US FDA dosing for PsA; prescriber attestation if inability to self‑administer is claimed (explanation required); patient not receiving Cimzia in combination with another systemic targeted immunomodulator for same indication; authorization will be issued for 12 months.

    Continuation requires documentation of benefit and adherence to dosing.

    Continuation therapy:
    Documentation of positive clinical response; Cimzia initiated and titrated per US FDA dosing for AS or nr‑axSpA; prescriber attestation if inability to self‑administer is claimed (explanation required); patient not receiving Cimzia in combination with another systemic targeted immunomodulator for same indication; authorization will be issued for 12 months.

    Continuation requires documentation of clinical benefit and adherence to dosing.

    Prescriber attestation and dermatology involvement required for this pathway.

    Continuation therapy: Documentation of positive clinical response; Cimzia initiated and titrated per US FDA dosing for PS; prescriber attestation if inability to self‑administer is claimed (explanation required); patient not receiving Cimzia in combination with another systemic targeted immunomodulator for same indication; authorization will be issued for 12 months.

    Continuation requires documentation of clinical benefit and adherence to dosing.

    Prescriber attestation that patient or caregiver cannot be trained or are physically unable to self‑administer Cimzia (explanation required); Cimzia per FDA dosing; patient not receiving Cimzia with another systemic targeted immunomodulator for same indication; prescribed by or in consultation with a dermatologist; initial authorization 12 months. Continuation requires documentation of positive clinical response and same attestation/dosing/combination restrictions; authorization 12 months.

    From policy: applies when self‑administration is not feasible or attested.

    Continuation requires prior Cimzia exposure and documentation of clinical benefit.

  1. Lack of documentation of positive clinical response may result in denial or reduced authorization duration.
  2. Prior Authorization

    Prior Authorization Requirements

    All prior authorization requests must document that the patient meets the coverage criteria for the requested indication. This includes the specific diagnosis, required prior trials or intolerances, dosing per FDA labeling, absence of contraindicated concurrent systemic targeted immunomodulators for the same indication, and any required prescriber attestations or specialist involvement.

    • Document prior treatment history (agents, doses, durations, and reason for discontinuation: lack of response, intolerance, or contraindication).
    • Confirm Cimzia dosing and titration per FDA labeling for the indicated condition.
    • If request is for combination therapy with another systemic targeted immunomodulator for the same indication, state that combination therapy is NOT allowed.
    Billing Rule

    Use Listed ICD-10 Diagnosis Code

    Use the applicable ICD-10-CM diagnosis code(s) that correspond specifically to the patient’s diagnosed site and subclass. Missing or incorrect diagnosis coding may result in nonpayment or denial of the request.

    • Select one of the listed ICD-10 codes from the policy's coding section that matches the diagnosed condition and anatomic site.
    • Ensure codes are current and specific (site, laterality, and complication codes where applicable).
    Denial Risk

    Denial Triggers

    Failure to provide required information may trigger denial. Common denial triggers include missing prescriber attestation when required, absence of documentation of prior therapies or trial durations, lack of specialist consultation when indicated, use of non‑covered combination systemic targeted immunomodulators for the same indication, and failure to document positive response for continuation requests.

    • Missing prescriber attestation (explanation why patient/caregiver cannot self‑administer) may result in denial.
    • Requesting Cimzia in combination with another systemic targeted immunomodulator for the same indication may result in denial.
    • Insufficient prior-treatment documentation or missing objective response data for renewals may result in denial.
    Documentation Required

    Prescriber Attestation and Specialty Involvement

    Certain indications require a prescriber attestation that the patient or caregiver cannot be trained or is physically unable to administer Cimzia for self-administration. When required, the attestation must include an explanation and, for some indications, the request must be prescribed by or in consultation with a specialist (gastroenterologist, rheumatologist, or dermatologist as specified by indication).

    • Submit a written prescriber attestation explaining why the patient or caregiver cannot self-administer when applicable.
    • Indication-specific specialist requirement examples: Crohn's disease – gastroenterologist; PsA, AS, nr-axSpA, PJIA – rheumatologist; Plaque psoriasis – dermatologist or consultation with dermatologist.
    • Failure to include required attestation or specialist consultation documentation may result in denial.
    Billing Rule

    Code-Specific Documentation Guidance

    Code-specific documentation must align the selected ICD-10-CM diagnosis code with the clinical diagnosis and site. Provide medical record evidence supporting the coded diagnosis (e.g., physical exam findings, imaging reports, lab results) to avoid coding-related denials.

    • Ensure the ICD-10 code selected matches the diagnosed condition and anatomic site/subclass.
    • Attach supporting documentation (notes, test results) that corroborate the diagnosis code.
    Step Therapy

    Required Prior Trials for Initial Therapy

    Initial therapy requests must document required prior trials unless the patient meets an alternative pathway (e.g., prior systemic targeted immunomodulator exposure or current use of Cimzia). Examples: Crohn's disease requires inadequate response to conventional therapies; RA requires failure/intolerance to a 3‑month trial of a non-biologic DMARD or prior biologic; PsA and psoriatic conditions require methotrexate trial or prior systemic targeted immunomodulator as specified.

    • Provide dates, agents, doses, and reasons for discontinuation of prior therapies.
    • If prior trials were not completed due to contraindication or adverse effects, include clinical rationale.
    • If patient previously received an FDA‑approved systemic targeted immunomodulator for the indication, include details of that therapy.
    Step Therapy

    Step Requirements for Plaque Psoriasis

    For plaque psoriasis, step requirements include failure of topical therapy and a 3‑month trial of methotrexate at maximally indicated dose unless contraindicated or intolerant. Alternatively, prior treatment with an FDA‑approved systemic targeted immunomodulator for plaque psoriasis is an acceptable pathway.

    • Document failure of topical agents (examples listed in policy) and the methotrexate 3‑month trial with dose and response.
    • If methotrexate is contraindicated or not tolerated, provide supporting clinical rationale and documentation.
    Step Therapy

    Step Therapy Note

    Step therapy note: when documenting prior therapies, include examples and lists of systemic targeted immunomodulators relevant to each indication. Requests for combination therapy with another systemic targeted immunomodulator for the same indication will not meet criteria.

    • Examples of systemic targeted immunomodulators (non-exhaustive) appear in the policy per indication — reference the policy lists when documenting prior biologic exposure.
    • Concurrent use of Cimzia plus another systemic targeted immunomodulator for the same indication is not permitted and will be a basis for denial.

    Initial Therapy — additional initial therapy requirements and disease severity/dosing notes

    Initial therapy requirements vary by indication; must follow FDA dosing, meet disease severity and prior therapy/attestation requirements, and avoid combination targeted immunomodulators.

    PS initial therapy — severity and step requirements: For plaque psoriasis initial therapy pathways: diagnosis of moderate to severe plaque psoriasis AND either ≥3% BSA involvement or special‑site involvement (palmoplantar, facial, genital, or severe scalp) with failure of at least one topical therapy (specified list) AND failure of a 3‑month methotrexate trial at maximally indicated dose unless contraindicated; OR prior treatment with an FDA‑approved systemic targeted immunomodulator for PS; OR patient currently on Cimzia; Cimzia per FDA dosing; not used in combination with another systemic targeted immunomodulator for same indication; initial authorization 12 months.>= 3% BSA

    Encodes the disease severity and methotrexate step requirements for PS.

    PJIA initial therapy specifics: For polyarticular juvenile idiopathic arthritis: diagnosis of active PJIA and Cimzia initiated/titrated per FDA dosing; not combined with another systemic targeted immunomodulator; prescriber attestation and rheumatology involvement when self‑administration is not feasible; initial authorization up to 12 months.

    From PJIA criteria in policy.

    Initial therapy / prior biologic examples

    Initial therapy coverage criteria reference prior treatment with or exclusion of specific systemic targeted immunomodulators; the policy updated example agent lists by indication.

    Examples of prior biologic/systemic targeted immunomodulators: Policy includes updated example lists of systemic targeted immunomodulators that either must have been previously tried for initial therapy pathways or must not be used in combination with Cimzia for the same indication. Examples added or updated across indications include vedolizumab, mirikizumab, guselkumab, bimekizumab, secukinumab, ixekizumab, deucravacitinib, tildrakizumab, brodalumab and others; some agents were removed or renamed per the summary of changes.

    Exact per‑indication lists and prior‑trial expectations are detailed in the indication sections of the policy.

    IndicationRequired prior trial(s) or prior targeted immunomodulator
    Crohn's disease (moderately to severely active)History of failure to one conventional therapy (e.g., corticosteroids) at up to maximally indicated doses unless contraindicated; OR prior treatment with an FDA‑approved systemic targeted immunomodulator for Crohn's disease; OR currently on Cimzia.
    Rheumatoid arthritis (moderately to severely active)History of failure/intolerance to a 3‑month trial of one non‑biologic DMARD (e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine) at maximally indicated doses unless contraindicated; OR prior treatment with an FDA‑approved systemic targeted immunomodulator for RA (e.g., adalimumab, etanercept, baricitinib, abatacept, upadacitinib, golimumab, tofacitinib); OR currently on Cimzia.
    Psoriatic arthritis (active)History of failure to a 3‑month trial of methotrexate at the maximally indicated dose unless contraindicated; OR prior treatment with an FDA‑approved systemic targeted immunomodulator for PsA (examples: adalimumab, bimekizumab, secukinumab, etanercept, abatacept, apremilast, upadacitinib, golimumab, risankizumab, ixekizumab, guselkumab, tofacitinib); OR currently on Cimzia.
    Ankylosing spondylitis / non‑radiographic axial spondyloarthritis (active)History of failure to two NSAIDs (each used ≥4 weeks at maximally indicated doses) unless contraindicated; OR prior treatment with an FDA‑approved systemic targeted immunomodulator for AS/nr‑axSpA (examples: adalimumab, bimekizumab, secukinumab, etanercept, baricitinib, abatacept, golimumab, upadacitinib, ixekizumab, tofacitinib); OR currently on Cimzia.
    Plaque psoriasis (moderate to severe)Either: (1) ≥3% BSA or special‑site involvement (palmoplantar, facial, genital, severe scalp) AND history of failure to ≥1 topical therapy (e.g., corticosteroids, vitamin D analogs, tazarotene, calcineurin inhibitors, anthralin, coal tar) AND history of failure to a 3‑month trial of methotrexate at maximally indicated dose unless contraindicated; OR (2) prior treatment with an FDA‑approved systemic targeted immunomodulator for plaque psoriasis; OR (3) currently on Cimzia.
    Plaque psoriasis requirementDetails
    Topical therapy failureHistory of failure to one topical therapy unless contraindicated; acceptable topical agents listed include corticosteroids (e.g., betamethasone, clobetasol, desonide), vitamin D analogs (e.g., calcitriol, calcipotriene), tazarotene, calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), anthralin, coal tar.
    Methotrexate trialHistory of failure to a 3‑month trial of methotrexate at the maximally indicated dose unless contraindicated or clinically significant adverse effects are experienced.
    Alternative pathwaysInstead of the topical + methotrexate pathway, prior treatment with an FDA‑approved systemic targeted immunomodulator for plaque psoriasis, or current use of Cimzia, also satisfy initial therapy requirements.
    IndicationUpdated examples of systemic targeted immunomodulators (prior treatment or prohibited combination)
    Crohn's diseaseUpdated examples added for combination/prohibition and prior treatment: added vedolizumab (Entyvio), mirikizumab (Omvoh), guselkumab (Tremfya); removed etanercept (Enbrel), baricitinib (Olumiant), abatacept (Orencia), golimumab (Simponi), tofacitinib (Xeljanz); 'ustekinumab' naming standardized.
    Psoriatic arthritisExamples revised: added bimekizumab (Bimzelx); removed baricitinib (Olumiant); standardized naming for ustekinumab; Xeljanz listed as Xeljanz/XR where applicable.
    Ankylosing spondylitis / nr‑axSpAExamples revised: added bimekizumab (Bimzelx), secukinumab (Cosentyx), ixekizumab (Taltz); updated prior‑treatment examples to include enbrel (etanercept), baricitinib (Olumiant), abatacept (Orencia), ixekizumab (Taltz); Xeljanz replaced with Xeljanz/Xeljanz XR (tofacitinib).
    Plaque psoriasisExamples revised: added bimekizumab (Bimzelx), deucravacitinib (Sotyktu); removed baricitinib (Olumiant), abatacept (Orencia), upadacitinib (Rinvoq), golimumab (Simponi), tofacitinib (Xeljanz); prior‑treatment examples added bimekizumab, secukinumab (Cosentyx), etanercept (Enbrel), tildrakizumab (Ilumya), brodalumab (Siliq), deucravacitinib (Sotyktu), ixekizumab (Taltz); 'ustekinumab' naming standardized.
    Polyarticular juvenile idiopathic arthritisUpdated example lists reflect replacement of Xeljanz (tofacitinib) with Xeljanz/Xeljanz XR naming and other example list adjustments per Summary of Changes.

    Continuation pathways mirror initial‑therapy combination restrictions and require evidence of benefit.

    Indications / Continuation — FDA-labeled indications and continuation rationale

    FDA‑labeled indications and standard continuation rationale (document notes FDA approvals but states FDA approval alone is not a basis for coverage).

    FDA‑labeled indications (reference): Cimzia is FDA‑indicated for: Crohn's disease; moderately to severely active rheumatoid arthritis; active psoriatic arthritis; active ankylosing spondylitis; active non‑radiographic axial spondyloarthritis with objective signs of inflammation; moderate‑to‑severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy; and active polyarticular juvenile idiopathic arthritis in patients ≥2 years of age. FDA approval alone is informational and not by itself a basis for coverage under this policy.

    Continuation coverage remains subject to meeting the policy's medical necessity criteria and member benefit terms.

    Rheumatoid arthritis (moderately to severely active)
    DefinitionModerately to severely active rheumatoid arthritis
    Initial therapy contextDiagnosis of moderately to severely active RA and Cimzia initiated/titrated per FDA labeled dosing
    Combination therapy restrictionPatient must not be receiving Cimzia in combination with another systemic targeted immunomodulator for the same indication
    Moderate to severe plaque psoriasis (definition)
    DefinitionModerate to severe plaque psoriasis defined by >=3% BSA or involvement of palmoplantar, facial, genital, or severe scalp psoriasis
    Role in initial therapyThese criteria are used within the initial therapy pathway which also requires prior topical therapy failure or alternative pathways (e.g., prior systemic targeted immunomodulator)
    Authorization implicationMeets severity threshold to consider Cimzia per policy when other criteria (prior therapy, dosing) are satisfied
    Rheumatoid myopathy / polyneuropathy (code context)
    Definition contextRheumatoid myopathy and rheumatoid polyneuropathy codes (M05.43x, M05.55x series) denote muscle or nerve involvement associated with rheumatoid arthritis and are specified by anatomical site
    Coding implicationUse the appropriate M05.43x / M05.55x code corresponding to the anatomic site when submitting claims/authorizations
    Policy relevanceListed codes support indication/subclassification for RA‑related muscle or nerve involvement in this policy's applicable ICD‑10 code set
    Juvenile rheumatoid arthritis (M08.xx series)
    Code seriesJuvenile rheumatoid arthritis represented by M08.xx series (e.g., M08.00, M08.011, M08.021, ... M08.972)
    Clinical meaningM08.xx codes specify site and subtype for pediatric‑onset forms of rheumatoid disease used for pJIA claims/authorization
    Authorization notepJIA coverage criteria reference FDA dosing and specialty involvement; use appropriate M08.xx code for documentation
    Ankylosing spondylitis (M45.x series)
    Code seriesAnkylosing spondylitis represented by M45.x series (e.g., M45.0–M45.8)
    Anatomic specificityM45.x codes specify spinal region involvement (multiple sites, cervical, thoracic, lumbar, sacral regions)
    Policy relevanceUse the appropriate M45.x code when submitting requests for AS or nr‑axSpA indications
    Cimzia (certolizumab pegol) — drug descriptor
    Generic descriptorCimzia (certolizumab pegol) is a recombinant humanized antibody Fab' fragment PEGylated to increase half‑life
    Mechanism featuresBinds and neutralizes TNFα; lacks an Fc region and therefore does not fix complement or cause antibody‑dependent cell‑mediated cytotoxicity in vitro
    Indication summaryApproved for multiple inflammatory conditions including Crohn's disease, RA, PsA, AS/nr‑axSpA, plaque psoriasis, and pJIA

    The revision also updates and clarifies the example lists of systemic targeted immunomodulators that must not be used in combination with Cimzia for the same indication. Across indications the policy added agents (for example, vedolizumab, mirikizumab, guselkumab, bimekizumab, secukinumab, ixekizumab, deucravacitinib, and others), removed some agents (for example, baricitinib in selected lists), and standardized naming (e.g., replacing branded formatting such as 'Stelara (ustekinumab)' with 'ustekinumab'). These operational changes affect prior authorization review and potential denial triggers when combination therapy or missing attestation documentation is present.